News Release

Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma

Peer-Reviewed Publication

Compuscript Ltd

https://doi.org/10.1016/j.apsb.2023.10.010

 

This new article publication from Acta Pharmaceutica Sinica B, discusses how targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma.

 

 

This study examines inhibiting galectin 1 (Gal1) as a treatment option for hepatocellular carcinoma (HCC). Gal1 has immunosuppressive and cancer-promoting roles. The data showed that Gal1 was highly expressed in human and mouse HCC. The levels of Gal1 positively correlated with the stages of human HCC and negatively with survival.

 

The roles of Gal1 in HCC were studied using overexpression (OE) or silencing using Igals1 siRNA delivered by AAV9. Prior to HCC initiation induced by RAS and AKT mutations, lgals1-OE and silencing had opposite impacts on tumor load. The treatment effect of lgals1 siRNA was further demonstrated by intersecting HCC at different time points when the tumor load had already reached 9% or even 42% of the body weight.

 

Comparing spatial transcriptomic profiles of Gal1 silenced and OE HCC, inhibiting matrix formation and recognition of foreign antigen in CD45+ cell-enriched areas located at tumor-margin likely contributed to the anti-HCC effects of Gal1 silencing. Within the tumors, silencing Gal1 inhibited translational initiation, elongation, and termination. Furthermore, Gal1 silencing increased immune cells as well as expanded cytotoxic T cells within the tumor, and the anti-HCC effect of lgals1 siRNA was CD8-dependent. Overall, Gal1 silencing has a promising potential for HCC treatment.

 

 

Keywords: Liver, Hepatocellular carcinoma, Carbohydrate-binding lectin, Galectin 1, Extracellular matrix, Translation, Spatial transcriptomics, Tumor-margin

Graphical Abstract: available at https://ars.els-cdn.com/content/image/1-s2.0-S2211383523004045-ga1_lrg.jpg   

Targeting Gal1 is effective in preventing as well as treatment of HCC and has translational potential.

# # # # # #

The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association.

For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/

Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board

 

APSB is available on ScienceDirect (https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).

 

Submissions to APSB may be made using Editorial Manager® (https://www.editorialmanager.com/apsb/default.aspx).

 

CiteScore: 19.4

Impact Factor: 14.5

JIF without self-citation: 13.7

ISSN 2211-3835

 # # # # #

Tahereh Setayesh, Ying Hu, Farzam Vaziri, Xin Chen, Jinping Lai, Dongguang Wei, Yu-Jui Yvonne Wan, Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma, Acta Pharmaceutica Sinica B, Volume 14, Issue 1, 2024, Pages 292-303, ISSN 2211-3835, https://doi.org/10.1016/j.apsb.2023.10.010


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.